Validation of a new prognostic index for patients with chronic lymphocytic leukemia
Open Access
- 7 January 2009
- Vol. 115 (2), 363-372
- https://doi.org/10.1002/cncr.24004
Abstract
BACKGROUND: The clinical course of chronic lymphocytic leukemia (CLL) is highly variable. A prognostic index based on widely available clinical and laboratory features was recently developed to predict survival among patients with previously untreated CLL. This index requires validation in an independent series of patients before widespread use can be recommended. METHODS: The Mayo Clinic CLL database was used to evaluate the validity and reproducibility of the new prognostic index. RESULTS: A total of 440 patients with newly diagnosed CLL who were seen at the Mayo Clinic within 12 months of diagnosis and for whom data were available with which to calculate index score were identified. Patients were classified as low, intermediate, or high risk using the prognostic index. The estimated median survival times were: not reached for low risk, 10.1 years for intermediate risk, and 7.2 years for high risk. The estimated median and 5‐year survival by prognostic index risk category were similar to those originally reported. The prognostic index risk category added predictive value beyond that of Rai risk alone (P = .004). The prognostic index risk category remained a predictor of survival when analysis was limited to Rai stage 0 (P = .03) and nonreferred patients (P < .0001) and also predicted time to treatment (P < .0001). CONCLUSIONS: The results of the current study confirm the ability of a newly developed prognostic index to predict survival among patients with previously untreated CLL. The study also extended the utility of the index by demonstrating that it is useful at diagnosis, retains prognostic value when applied exclusively to Rai stage 0 patients, is effective in nonreferred patients, and predicts time to treatment. Cancer 2009. © 2009 American Cancer Society.Keywords
This publication has 37 references indexed in Scilit:
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008
- The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphomaBritish Journal of Haematology, 2008
- Prognostic importance of T and NK‐cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemiaBritish Journal of Haematology, 2008
- CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potentialBritish Journal of Haematology, 2008
- Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemiaBlood, 2008
- Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemiaBritish Journal of Haematology, 2007
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005
- Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six GenesNew England Journal of Medicine, 2004
- Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLLBlood, 2004
- A clinical staging system for chronic lymphocytic leukemia.Prognostic significanceCancer, 1977